ProPhase Cash Conversion Cycle from 2010 to 2024

PRPH Stock  USD 0.77  0.01  1.28%   
ProPhase Labs' Cash Conversion Cycle is increasing with very volatile movements from year to year. Cash Conversion Cycle is predicted to flatten to 201.80. For the period between 2010 and 2024, ProPhase Labs, Cash Conversion Cycle quarterly trend regression had mean deviation of  54.56 and range of 251. View All Fundamentals
 
Cash Conversion Cycle  
First Reported
2010-12-31
Previous Quarter
226.75490908
Current Value
201.8
Quarterly Volatility
68.93346239
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check ProPhase Labs financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among ProPhase Labs' main balance sheet or income statement drivers, such as Interest Expense of 1.3 M, Selling General Administrative of 32.8 M or Total Revenue of 35.5 M, as well as many indicators such as Price To Sales Ratio of 1.66, Dividend Yield of 0.067 or PTB Ratio of 1.5. ProPhase financial statements analysis is a perfect complement when working with ProPhase Labs Valuation or Volatility modules.
  
Check out the analysis of ProPhase Labs Correlation against competitors.
For more detail on how to invest in ProPhase Stock please use our How to Invest in ProPhase Labs guide.

Latest ProPhase Labs' Cash Conversion Cycle Growth Pattern

Below is the plot of the Cash Conversion Cycle of ProPhase Labs over the last few years. It is ProPhase Labs' Cash Conversion Cycle historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in ProPhase Labs' overall financial position and show how it may be relating to other accounts over time.
Cash Conversion Cycle10 Years Trend
Very volatile
   Cash Conversion Cycle   
       Timeline  

ProPhase Cash Conversion Cycle Regression Statistics

Arithmetic Mean173.08
Geometric Mean158.88
Coefficient Of Variation39.83
Mean Deviation54.56
Median169.77
Standard Deviation68.93
Sample Variance4,752
Range251
R-Value0.07
Mean Square Error5,092
R-Squared0
Significance0.80
Slope1.08
Total Sum of Squares66,526

ProPhase Cash Conversion Cycle History

2024 201.8
2023 226.75
2022 96.73
2021 154.97
2020 52.38
2019 303.76
2018 280.96

About ProPhase Labs Financial Statements

Investors use fundamental indicators, such as ProPhase Labs' Cash Conversion Cycle, to determine how well the company is positioned to perform in the future. Although ProPhase Labs' investors may analyze each financial statement separately, they are all interrelated. Understanding these patterns can help investors make the right trading decisions.
Last ReportedProjected for Next Year
Cash Conversion Cycle 226.75  201.80 

Currently Active Assets on Macroaxis

When determining whether ProPhase Labs offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of ProPhase Labs' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Prophase Labs Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Prophase Labs Stock:
Check out the analysis of ProPhase Labs Correlation against competitors.
For more detail on how to invest in ProPhase Stock please use our How to Invest in ProPhase Labs guide.
You can also try the Instant Ratings module to determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of ProPhase Labs. If investors know ProPhase will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about ProPhase Labs listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
(0.95)
Earnings Share
(1.53)
Revenue Per Share
0.996
Quarterly Revenue Growth
(0.81)
Return On Assets
(0.23)
The market value of ProPhase Labs is measured differently than its book value, which is the value of ProPhase that is recorded on the company's balance sheet. Investors also form their own opinion of ProPhase Labs' value that differs from its market value or its book value, called intrinsic value, which is ProPhase Labs' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because ProPhase Labs' market value can be influenced by many factors that don't directly affect ProPhase Labs' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between ProPhase Labs' value and its price as these two are different measures arrived at by different means. Investors typically determine if ProPhase Labs is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, ProPhase Labs' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.